- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01695707
Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
Rochester, New York, United States, 14642
- University of Rochester Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
i. Moderate to Severe AD: EASI ≥ 10 ii. Active Atopic Dermatitis: Subjects must have within the last 3 months according to medical records or by medical exam of the investigator:
- Pruritus
- Eczema (acute, subacute, chronic)
I. Typical morphology and age-specific patterns - Patterns include (1) facial, neck, and extensor involvement in infants and children, (2) current or prior flexural lesions in any age group, (3) sparing groin and axillary regions.
II. Chronic or relapsing history
iii. Extrinsic they must also meet both of the following: serum total IgE ≥ 1.5 S.D. greater than the age-matched norms and positive multi-allergen RAST (Phadiatop).
Additionally, subjects must have TEWL of nonlesional skin of upper arm that is ≥ 8 gm/m2/h at screening visit. This is to ensure that we are in fact studying the subset of AD subjects who have a skin barrier defect.
Exclusion Criteria:
- Unwillingness or inability to complete the Informed Consent process
- Subjects with a history of keloid formation
- History of lidocaine or Novocain allergy
- Subjects with a systemic infection requiring a course of systemic antibiotics or antivirals within the last 2 weeks
- Subjects with MD diagnosed Type 1 or 2 diabetes mellitus
- Subjects with NYHA class III or IV cardiac status
- Subjects with a history of liver disease (EtOH, viral hepatitis, drug-induced hepatitis or other)
- Subjects with evidence of an underlying systemic disease based on history and physical (other than the above diagnostic categories (and associated allergic disorders), or well-controlled hypertension, or hyperlipidemia).
- History of cancer other than nonmelanomatous skin cancer or cervical dysplasia
- Participants enrolled while on a systemic treatment for their atopic dermatitis (e.g. cyclosporine, mycophenolate mofetil) must remain on a stable dose for the duration of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Subjects randomized to placebo will receive opaque size "00" gelatin capsules containing 240mg lactose.
As with the intervention group, 1 capsule will be taken by each day throughout the treatment period.
|
see Arm Description
|
Experimental: Pioglitazone
Subjects randomized to pioglitazone will receive opaque size "00" gelatin capsules containing pioglitazone. For the first 3 weeks, capsules will contain 30 mg pioglitazone. For the remaining 9 weeks of the treatment period, capsules will contain 45 mg pioglitazone unless subjects are unable to tolerate this increased dose. One capsule will be taken by each day throughout the treatment period. |
see Arm Description
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
---|---|
Noninvasive barrier measurements (TEWL)
|
Transepidermal Water Loss (TEWL) will be measured at multiple time points throughout the study as a surrogate for skin barrier integrity.
|
Transepithelial electrical resistance (TEER) and permeability
|
Skin biopsies will be performed twice during the study.
The integrity of the skin barrier will be assessed in the lab by transepithelial electrical resistance (TEER) and permeability of the biopsy specimens.
|
mRNA
|
Ex vivo assessment of mRNA expression of key epidermal barrier proteins will also be performed on the biopsy specimens.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
---|---|
Skin Irritancy
|
The clinical efficacy of PIO will be assessed by quantifying the skin response to a model irritant, sodium lauryl sulphate (SLS) at several time points.
Subjects will be exposed for 24 h on the dominant inner arm to SLS at three concentrations (wt/vol in water - 0.125, 0.5 and 2%) (Fluka) using standard patch test reagents (Finn chambers of 18-mm diam, Filter Discs & Scanpor tape).
Before application and at several time points after removal, TEWL and erythema will be measured at the exposed site and at a control site.
Erythema will be measured using a colorimeter (Minolta CR-200).
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Lisa A Beck, MD, University of Rochester
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RSRB00041078
- 1R21AR062357 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
ShaperonRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of ScalpUnited States
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
AmgenCompletedDermatitis, Atopic DermatitisCanada, United States, Japan
-
Hadassah Medical OrganizationUnknownATOPIC DERMATITIS
-
SanofiCompletedAtopic Dermatitis | Dermatitis AtopicChina
-
SanofiCompletedDermatitis AtopicSaudi Arabia, Kuwait, United Arab Emirates
-
National Institute of Allergy and Infectious Diseases...Atopic Dermatitis Research NetworkCompletedAtopic Dermatitis (AD) | Non-atopic Healthy ControlsUnited States
Clinical Trials on Placebo (for pioglitazone)
-
Merck Sharp & Dohme LLCCompletedNon-alcoholic Fatty Liver Disease
-
Solvay PharmaceuticalsCompletedType 2 Diabetes MellitusUnited Kingdom
-
University of VermontTakedaCompleted
-
University of Texas Southwestern Medical CenterNational Institutes of Health (NIH)Completed
-
University at BuffaloTakeda Pharmaceuticals North America, Inc.Completed
-
Medical University of South CarolinaTakeda Pharmaceuticals North America, Inc.CompletedDiabetesUnited States
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceNot yet recruitingANCA Associated Vasculitis | Rapidly Progressive Glomerulonephritis | Crescentic Glomerulonephritis
-
TakedaZinfandel Pharmaceuticals Inc.TerminatedMild Cognitive Impairment Due to Alzheimer's DiseaseUnited States, Germany, Switzerland, United Kingdom, Australia
-
Dong-A ST Co., Ltd.CompletedType 2 DiabetesKorea, Republic of
-
IKFE Institute for Clinical Research and DevelopmentTakeda; Heidelberg University; Johannes Gutenberg University MainzCompletedCardiovascular Disease | Type 2 Diabetes MellitusGermany